Twin Tree Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-242,150
| Closed | -$33.8M | – | 1458 |
|
|
2025
Q2 | $33.8M | Sell |
242,150
-88,600
| -27% | -$12.4M | 0.06% | 311 |
|
|
2025
Q1 | $48.6M | Buy |
+330,750
| New | +$47.9M | 0.09% | 180 |
|
|
2024
Q2 | – | Sell |
-85,200
| Closed | -$11.5M | – | 1340 |
|
|
2024
Q1 | $11.5M | Sell |
85,200
-365,950
| -81% | -$48.5M | 0.03% | 598 |
|
|
2023
Q4 | $60.8M | Sell |
451,150
-93,150
| -17% | -$12.1M | 0.12% | 174 |
|
|
2023
Q3 | $73.7M | Buy |
+544,300
| New | +$74.3M | 0.17% | 117 |
|
|
2023
Q1 | – | Sell |
-625,450
| Closed | -$84.8M | – | 1274 |
|
|
2022
Q4 | $84.8M | Sell |
625,450
-206,950
| -25% | -$26M | 0.18% | 83 |
|
|
2022
Q3 | $91.3M | Buy |
832,400
+44,850
| +6% | +$5.69M | 0.17% | 86 |
|
|
2022
Q2 | $104M | Buy |
787,550
+428,150
| +119% | +$56.2M | 0.17% | 69 |
|
|
2022
Q1 | $47.7M | Buy |
359,400
+279,500
| +350% | +$33.5M | 0.08% | 202 |
|
|
2021
Q4 | $9.31M | Hold |
79,900
| – | – | 0.02% | 647 |
|
|
2021
Q3 | $9.6M | Sell |
79,900
-96,600
| -55% | -$11.2M | 0.02% | 590 |
|
|
2021
Q2 | $21.1M | Hold |
176,500
| – | – | 0.06% | 322 |
|
|
2021
Q1 | $17.6M | Buy |
+176,500
| New | +$17.7M | 0.07% | 311 |
|
|
2018
Q1 | – | Sell |
-91,250
| Closed | -$6.33M | – | 1096 |
|
|
2017
Q4 | $6.33M | Sell |
91,250
-20,600
| -18% | -$1.39M | 0.05% | 348 |
|
|
2017
Q3 | $7.58M | Buy |
+111,850
| New | +$7.07M | 0.06% | 286 |
|
|
2017
Q2 | – | Sell |
-37,650
| Closed | -$2.35M | – | 951 |
|
|
2017
Q1 | $2.35M | Buy |
+37,650
| New | +$2.19M | 0.02% | 521 |
|
|
2016
Q3 | – | Sell |
-22,400
| Closed | -$1.35M | – | 1140 |
|
|
2016
Q2 | $1.35M | Buy |
+22,400
| New | +$1.3M | 0.02% | 573 |
|
|
2015
Q1 | – | Sell |
-28,600
| Closed | -$2.01M | – | 1139 |
|
|
2014
Q4 | $2.01M | Sell |
28,600
-74,200
| -72% | -$5.31M | 0.06% | 375 |
|
|
2014
Q3 | $7.34M | Sell |
102,800
-24,500
| -19% | -$1.79M | 0.2% | 96 |
|
|
2014
Q2 | $9.46M | Buy |
127,300
+111,200
| +691% | +$8.04M | 0.21% | 83 |
|
|
2014
Q1 | $1.04M | Sell |
16,100
-47,200
| -75% | -$3.05M | 0.02% | 613 |
|
|
2013
Q4 | $3.76M | Buy |
63,300
+49,000
| +343% | +$2.66M | 0.09% | 235 |
|
|
2013
Q3 | $743K | Sell |
14,300
-7,500
| -34% | -$377K | 0.03% | 531 |
|
|
2013
Q2 | $1.03M | Buy |
+21,800
| New | +$1.11M | 0.04% | 464 |
|
Other funds holding AZN
IA
VCM
VAM
Twin Tree Management's AZN Position: Q1 2026 in Review
Twin Tree Management increased its AstraZeneca (AZN) stake by 16% in Q1 2026, buying an estimated $309K and bringing the position to 11,420 shares worth $2.25M. The position accounts for 0.05% of the portfolio, ranked #436.
Twin Tree Management first reported a position in AZN in Q1 2014 and has held it in 36 quarters since. The position peaked at $37.8M in Q3 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Twin Tree Management held 11,420 shares of AstraZeneca worth $2.25M as of Q1 2026.
- Twin Tree Management bought 1,604 AstraZeneca shares in Q1 2026, an estimated $309K.
- AstraZeneca made up 0.05% of Twin Tree Management's portfolio in Q1 2026, its #436 holding.
- Twin Tree Management first reported a position in AstraZeneca in Q1 2014 and has held it in 36 quarters since.
- Twin Tree Management's AstraZeneca position peaked at $37.8M in Q3 2022.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Twin Tree Management's 13F filing for Q1 2026, filed 14 May 2026.